Download Paper
Erik Boldt is an Advanced R&D Scientist at Honeywell in Buffalo, New York where he leads the development of HFO-1234ze(E) in pharmaceutical applications. His current research focuses on formulation development, material compatibility, performance, and stability of metered dose inhalers using HFO-1234ze(E) as propellant. Erik received his Master’s degree in Medicinal Chemistry from the University at Buffalo and has been working in the pharmaceutical industry for over 5 years, including in drug development, clinical trials, and large-scale manufacturing.